Recalled HeartWare Heart Implants Pose Risk of Serious Injury, Death, FDA Warns
Federal regulators are warning about problems with HeartWare Ventricular Assist Device (HVAD), which recently led to two recalls due to the risk of severe injury or death.
This week, the FDA classified both as Class I medical device recalls, which is the most serious recall classification, suggesting that continued use of the HeartWare implants pose a risk of serious adverse events or death.
Did You Know?
Millions of Philips CPAP Machines Recalled
Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.Learn More
The HeartWare Ventricular Assist Device (HVAD) is designed to help pump blood from the heart to the rest of the body. It is used in patients who are at risk of death from end-stage left ventricular heart failure. These patients use the pump while waiting for a heart transplant.
The system includes a pump implanted in the space around the heart and a controller regulating the speed and function of the pump. It is designed to be used both in a hospital setting or during patient transport.
Both of the recent recalls involve problems caused by moisture entering the system.
The issues stem from a design issue with the driveline connector. The driveline is a tube that connects the pump to the external controller and power source. Contamination of the driveline may allow fluid or other material to enter the pump and cause electrical problems or cause the pump to stop completely.
The controller recall is similarly linked to a loose connector that could lead to the rear portion of the pump’s driveline connector to become separated from the front part of the connector. If moisture enters the system, it can result in corrosion, electrical issues, cause the speaker volume to be decreased and cause connection failures. A connection failure could cause the pump to stop, and if the speaker volume is reduced, the patient may not hear the device’s alarm, the FDA warns.
Electrical malfunctions or stopping the pump may lead to serious adverse health consequences, including death of the user, the FDA warns.
Heartware’s History of Recalls
HeartWare has a long history of being affected by faulty devices and numerous recalls. The company was involved with another class I recall last year which affected more than 1,700 units across the U.S. During that recall, the Ventricular Assist Systems malfunctioned due to bent pins in a faulty power supply connector port. The company received at least 33 reports of device malfunction, including one non-fatal injury.
Another recall was issued for the HeartWare device in August 2015. The recall was issued after reports of bleeds, blood clot complications, strokes and other injuries were linked to the devices. HeartWare reported they were conducting clinical trials to better evaluate the safety of their devices, yet continue to experience problems.
HeartWare VADs were affected by another recall in 2014. The devices were recalled after a defect caused two deaths and four serious injuries. That recall was also initiated because of a defective driveline connector.
HeartWare was accused of dropping the ball on fixing the issues. Three years prior to the recall, HeartWare received at least 27 complaints about the controller of the pumps.
Users and customers affected by the most recent recall or who have experienced adverse health effects can contact the FDA via the MedWatch Adverse Event Reporting Program online or at 800-FDA-0178.
"*" indicates required fields
More Top Stories
Uber faces a lawsuit from four passengers who say they were sexually assaulted by drivers, due to the company's lack of security measures and focus on passenger safety.
A Bard PowerPort lawsuit claims the defective design of the port catheter led to a woman developing a severe infection and needing to have the implant surgically removed.
The new federal judge overseeing all talcum powder lawsuits has called for a Science Day to educate the court ahead of planned Daubert hearings which could decide if bellwether test trials can move forward.